You are here
Ariad's TKI: ponatinib- PACE, a phase 11 clinical trial
A pivotal Phase 2 clinical trial of ARIAD’s investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), is ongoing in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
5em; ">A pivotal Phase 2 clinical trial of ARIAD’s investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), is ongoing in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
The PACE (Ponatinib Ph+ ALL and CML Evaluation) trial is designed to provide definitive clinical data for regulatory approval of ponatinib in this setting. Ponatinib has been granted orphan drug status in both the United States and Europe for the treatment of CML and Ph+ ALL.....more http://www.ariad.com/wt/tertiarypage/pace